Article ; Online: Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.
2021 Volume 205, Page(s) 120–127
Abstract: ... COVID-19 patients, exposure to enoxaparin is reduced due to an increase in the volume of distribution ... of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-19 ICU ... from consecutive patients with laboratory-confirmed SARS-CoV-2 infection treated with enoxaparin for the prevention ...
| Abstract | Background: In intensive-care unit (ICU) patients, pathophysiological changes may affect the pharmacokinetics of enoxaparin and result in underdosing. Objectives: To develop a pharmacokinetic model of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-19 ICU-patients. Methods: This was a retrospective study in ICUs of two French hospitals. Anti-Xa activities from consecutive patients with laboratory-confirmed SARS-CoV-2 infection treated with enoxaparin for the prevention or the treatment of venous thrombosis were used to develop a population pharmacokinetic model using non-linear mixed effects techniques. Monte Carlo simulations were then performed to predict enoxaparin exposure at steady-state after three days of administration. Results: A total of 391 anti-Xa samples were measured in 95 patients. A one-compartment model with first-order kinetics best fitted the data. The covariate analysis showed that enoxaparin clearance (typical value 1.1 L.h-1) was related to renal function estimated by the CKD-EPI formula and volume of distribution (typical value 17.9 L) to actual body weight. Simulation of anti-Xa activities with enoxaparin 40 mg qd indicated that 64% of the patients had peak levels within the range 0.2 to 0.5 IU.mL-1 and 75% had 12-hour levels above 0.1 IU.mL-1. Administration of a total daily dose of at least 60 mg per day improved the probability of target attainment. Conclusion: In ICU COVID-19 patients, exposure to enoxaparin is reduced due to an increase in the volume of distribution and clearance. Consequently, enoxaparin 40 mg qd is suboptimal to attain thromboprophylactic anti-Xa levels. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Anticoagulants ; COVID-19 ; Critical Illness ; Enoxaparin/therapeutic use ; Humans ; Retrospective Studies ; SARS-CoV-2 | |||||
| Chemical Substances | Anticoagulants ; Enoxaparin | |||||
| Language | English | |||||
| Publishing date | 2021-07-21 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 121852-9 | |||||
| ISSN | 1879-2472 ; 0049-3848 | |||||
| ISSN (online) | 1879-2472 | |||||
| ISSN | 0049-3848 | |||||
| DOI | 10.1016/j.thromres.2021.07.010 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 863: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.